Actionable news
All posts from Actionable news
Actionable news in GBT: Global Blood Therapeutics Inc,

Roth Capital Maintains Positive Stance on Global Blood Therapeutics Inc (GBT) Following Updated Clinical Results for GBT440

Roth Capital analyst Mark Breidenbach is out today with a favorable report on shares of Global Blood Therapeutics Inc (NASDAQ:GBT), after the company provided updated results for GBT440, its investigational drug for patients with sickle cell anemia (SCA), at the 2016 ASH meeting.

Breidenbach noted, “In our view, these results were not the only good news at ASH for patients with hemoglobinopathies; several presentations were devoted to new earlystage drugs for SCA, with an emphasis on preventing clinical...